title: Review: new aminosalicylic acid derivatives for the treatment of inflammatory bowel disease.
abstract: Up to 20-30% of patients treated with sulphasalazine experience a variety of adverse effects, principally due to the carrier moiety sulphapyridine. In the last decade there has been a major drive to develop a new generation of 5-aminosalicylic acid (5-ASA) and 5-ASA-related drugs which not only have a high efficacy but are also devoid of the unwanted side-effects of sulphapyridine. Various forms of 5-ASA have been evaluated in ulcerative colitis and appear to be effective orally in preventing relapse and topically in the treatment of active distal colitis. More recently, topical 4-ASA has been found to be useful for the treatment of distal colitis with the advantage of better stability and lower cost compared with 5-ASA. In the foreseeable future it seems likely that these new aminosalicylic acid derivatives will become the drugs of choice in the treatment of inflammatory bowel disease and largely replace sulphasalazine.
authors.affiliation: Department of Gastroenterology, St Bartholomew's Hospital, West Smithfield, London, UK.
authors.forename: A S
authors.initials: AS
authors.lastname: Arvind
authors.forename: M J
authors.initials: MJ
authors.lastname: Farthing
mesh_terms: D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000636:Aminosalicylic Acids